⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Startup · Disruption threat: LOW
Paige AI is a pure-play AI pathology company whose entire product suite—including FDA-authorized prostate cancer detection tools—is built on deep learning models applied to digital pathology slides. The company continues to expand its clinical AI pipeline and partnerships with major cancer centers, making AI the core of its commercial and scientific identity.
Paige AI is a pure-play computational pathology company whose entire commercial identity is built on artificial intelligence. Its FDA-authorized prostate cancer detection tool, built on deep learning applied to whole slide digital pathology images, represents one of the most advanced clinical AI deployments in oncology diagnostics. With an overall AI score of 78/100, Paige sits firmly in the upper tier of AI-native healthcare companies. The score is anchored by exceptional performance across core dimensions. Product AI Integration scores 95/100, reflecting that AI is not supplementary but foundational to every offering. Revenue from AI reaches 90/100, confirming commercial traction beyond research-stage positioning. R&D AI Investment at 85/100 signals continued pipeline expansion, including AI biomarker discovery partnerships with major cancer centers. Internal AI Use at 70/100 and AI Infrastructure at 75/100 represent relative gaps, suggesting operational AI maturity still lags the product side. A LOW disruption threat rating is appropriate here. As an AI-native company, Paige faces minimal risk of being displaced by AI adoption trends that threaten legacy competitors. Its architecture already assumes AI at the center. The primary risk is regulatory and reimbursement pace. Clinical AI adoption depends on payer coverage decisions that remain inconsistent, creating a commercialization bottleneck despite strong scientific and technical positioning.
Full interactive analysis at RankVis.io